Featured Research

from universities, journals, and other organizations

EGF receptor ecto-domain mutations: When to screen and when not to screen

Date:
December 17, 2013
Source:
Landes Bioscience
Summary:
The epidermal growth factor receptor (EGFR) is expressed in normal colonic cells and is activated by specific peptide growth factors that regulate cell proliferation, survival and differentiation. Increased expression and activation of the EGFR has been observed in the majority of colorectal carcinoma, suggesting that the EGFR pathway plays an important role in colon carcinogenesis.

The epidermal growth factor receptor (EGFR) is expressed in normal colonic cells and is activated by specific peptide growth factors that regulate cell proliferation, survival and differentiation. Increased expression and activation of the EGFR has been observed in the majority of colorectal carcinoma (CRC), suggesting that the EGFR pathway plays an important role in colon carcinogenesis.

The monoclonal antibodies cetuximab and panitumumab are capable of blocking EGFR activity and have shown clinical activity in patients with metastatic CRC (mCRC). However, the efficacy of these agents is significantly limited by mechanisms of intrinsic and acquired resistance. In this respect, the S492R mutation of the extracellular domain of the EGFR is a peculiar mechanism of acquired resistance that limits the binding of cetuximab, but not panitumumab, to the EGFR.

This study is the first to demonstrate that the S492R EGFR ectodomain mutation is never present in patients that have not been exposed to EGFR monoclonal antibodies. In particular, a large cohort (505 patients) of KRAS exon 2 wild type mCRC cases, potential candidates for treatment with cetuximab, were screened to test for the S492R EGFR mutation; a sensitive test that failed to identify any mutation.

These findings suggest that the S492R EGFR mutation is not involved in primary resistance to cetuximab in CRC and have important consequences on the molecular assessment of mCRC patients. Based on these findings patients with mCRC should not be routinely screened for the S492R mutation prior therapy with cetuximab.


Story Source:

The above story is based on materials provided by Landes Bioscience. Note: Materials may be edited for content and length.


Journal Reference:

  1. Claudia Esposito, Anna Maria Rachiglio, Maria Libera La Porta, Alessandra Sacco, Cristin Roma, Alessia Iannaccone, Fabiana Tatangelo, Laura Forgione, Raffaella Pasquale, Americo Barbaro, Gerardo Botti, Fortunato Ciardiello, Nicola Normanno. The S492R EGFR ectodomain mutation is never detected in KRAS wild type colorectal carcinoma before exposure to EGFR monoclonal antibodies. Cancer Biology & Therapy, 2013; 14 (12) DOI: 10.4161/cbt.26340

Cite This Page:

Landes Bioscience. "EGF receptor ecto-domain mutations: When to screen and when not to screen." ScienceDaily. ScienceDaily, 17 December 2013. <www.sciencedaily.com/releases/2013/12/131217171004.htm>.
Landes Bioscience. (2013, December 17). EGF receptor ecto-domain mutations: When to screen and when not to screen. ScienceDaily. Retrieved October 23, 2014 from www.sciencedaily.com/releases/2013/12/131217171004.htm
Landes Bioscience. "EGF receptor ecto-domain mutations: When to screen and when not to screen." ScienceDaily. www.sciencedaily.com/releases/2013/12/131217171004.htm (accessed October 23, 2014).

Share This



More Health & Medicine News

Thursday, October 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Orthodontist Mom Jennifer Salzer on the Best Time for Braces

Orthodontist Mom Jennifer Salzer on the Best Time for Braces

Working Mother (Oct. 22, 2014) Is your child ready? Video provided by Working Mother
Powered by NewsLook.com
U.S. Issues Ebola Travel Restrictions, Are Visa Bans Next?

U.S. Issues Ebola Travel Restrictions, Are Visa Bans Next?

Newsy (Oct. 22, 2014) Now that the U.S. is restricting travel from West Africa, some are dropping questions about a travel ban and instead asking about visa bans. Video provided by Newsy
Powered by NewsLook.com
US to Track Everyone Coming from Ebola Nations

US to Track Everyone Coming from Ebola Nations

AP (Oct. 22, 2014) Stepping up their vigilance against Ebola, federal authorities said Wednesday that everyone traveling into the US from Ebola-stricken nations will be monitored for symptoms for 21 days. (Oct. 22) Video provided by AP
Powered by NewsLook.com
Doctors Help Paralysed Man Walk Again, Patient in Disbelief

Doctors Help Paralysed Man Walk Again, Patient in Disbelief

AFP (Oct. 22, 2014) Polish doctors describe how they helped a paralysed man walk again, with the patient in disbelief at the return of sensation to his legs. Duration: 1:04 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins